SpringerLink
Log in

Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

MDM2 SNP309 is a single nucleotide T > G polymorphism present in intron 1 of the MDM2 gene. A variety of case–control studies have been published evaluating the association between MDM2 SNP309 and breast cancer risk. However, the published studies, as well as the subsequent meta-analyses, have yielded contradictory results. This meta-analysis aims to examine whether MDM SNP309 polymorphism may exert a differential effect on breast cancer risk along with race. Eligible articles were identified by a search of MEDLINE, Cochrane and EMBASE bibliographical databases for the period July 1993 to June 2009; 16 case–control studies were eligible (12,986 breast cancer cases, 12,993 controls). Subanalyses in case–control studies conducted on Chinese (3 studies, 892 cases, 1,435 controls) and non-Chinese populations (13 studies, 12,094 cases, 11,558 controls) were performed. All pooled odds ratios (ORs) were derived from fixed-effects models given that the between-study heterogeneity was not statistically significant. Subanalysis on Chinese subjects demonstrated that GT and GG genotype were associated with increased breast cancer risk (pooled OR = 1.272, 95% CI 1.025–1.578 and pooled OR = 1.323, 95% CI 1.034–1.694, respectively); as a result the overall effect of the G allele was statistically significant (pooled OR = 1.287, 95% CI 1.048–1.579). On the contrary, no significant associations between MDM2 SNP309 status and breast cancer risk were demonstrated in non-Chinese populations. In conclusion, the association between MDM2 SNP309 and breast cancer is modified by race. MDM2 SNP309 represents a risk factor for breast cancer in Chinese women but not in non-Chinese women. This phenomenon is analogous to that described in the context of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21:307–315

    Article  CAS  PubMed  Google Scholar 

  2. Bouska A, Eischen CM (2009) Mdm2 affects genome stability independent of p53. Cancer Res 69:1697–1701

    Article  CAS  PubMed  Google Scholar 

  3. Agrawal A, Yang J, Murphy RF, Agrawal DK (2006) Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp Mol Pathol 81:115–122

    Article  CAS  PubMed  Google Scholar 

  4. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602

    Article  CAS  PubMed  Google Scholar 

  5. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911–919

    Article  CAS  PubMed  Google Scholar 

  6. Campbell IG, Eccles DM, Choong DY (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240:195–197

    Article  CAS  PubMed  Google Scholar 

  7. Millikan RC, Heard K, Winkel S, Hill EJ, Massa B, Mayes L, Williams P, Holston R, Conway K, Edmiston S, de Cotret AR (2006) No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15:175–177

    Article  CAS  PubMed  Google Scholar 

  8. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, ** G, Liu J, Wei Q, Shen H (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case–control analysis in a Chinese population. Cancer Lett 240:261–267

    Article  CAS  PubMed  Google Scholar 

  9. Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW, Eccles DM (2006) Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 6:80

    Article  PubMed  CAS  Google Scholar 

  10. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26:4975–4977

    CAS  PubMed  Google Scholar 

  11. Wilkening S, Bermejo JL, Burwinkel B, Klaes R, Bartram CR, Meindl A, Bugert P, Schmutzler RK, Wappenschmidt B, Untch M, Hemminki K, Forsti A (2006) The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66:646–648

    Article  CAS  PubMed  Google Scholar 

  12. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I (2007) The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health studies. Cancer Causes Control 18:621–625

    Article  PubMed  Google Scholar 

  13. Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M (2007) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 104:153–157

    Article  CAS  PubMed  Google Scholar 

  14. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, Van’t Veer LJ (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584–9590

    Article  CAS  PubMed  Google Scholar 

  15. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ (2008) MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111:497–504

    Article  CAS  PubMed  Google Scholar 

  16. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K (2008) MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:754–761

    Article  CAS  PubMed  Google Scholar 

  17. Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P, Nenutil R, Vojtesek B (2008) MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 74:84–87

    Article  CAS  PubMed  Google Scholar 

  18. Paulin FE, O’Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW, Munro AJ, Baker L, Purdie CA, Lane DP, Thompson AM (2008) MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 8:281

    Article  PubMed  CAS  Google Scholar 

  19. Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ (2009) Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 9:13

    Article  PubMed  CAS  Google Scholar 

  20. Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48–57

    Article  PubMed  Google Scholar 

  21. Hu Z, ** G, Wang L, Chen F, Wang X, Shen H (2007) MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case–control studies. Cancer Epidemiol Biomarkers Prev 16:2717–2723

    Article  CAS  PubMed  Google Scholar 

  22. Wilkening S, Bermejo JL, Hemminki K (2007) MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28:2262–2267

    Article  CAS  PubMed  Google Scholar 

  23. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  Google Scholar 

  24. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  CAS  PubMed  Google Scholar 

  25. Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T (2009) Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations. BMC Cancer 9:60

    Article  PubMed  CAS  Google Scholar 

  26. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66:5104–5110

    Article  CAS  PubMed  Google Scholar 

  27. Gui XH, Qiu LX, Zhang HF, Zhang DP, Zhong WZ, Li J, **ao YL (2009) MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. Eur J Cancer 45(11):2023–2026

    Google Scholar 

  28. Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, Glassman A, Sneige N, Albitar M (1996) Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat 37:179–188

    Article  CAS  PubMed  Google Scholar 

  29. Bai J, Dai J, Yu H, Shen H, Chen F (2009) Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J Toxicol Environ Health A 72:677–682

    Article  CAS  PubMed  Google Scholar 

  30. Casey PM, P.M. Cerhan PM, Pruthi S (2008) Oral contraceptive use and risk of breast cancer. Mayo Clin Proc 83:86–90; quiz 90-81

  31. Cleary MP, Grossmann ME (2009) Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150:2537–2542

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, National University of Athens, Athens, Greece

    Konstantinos P. Economopoulos & Theodoros N. Sergentanis

  2. Society of Junior Doctors, 5 Menalou Street, 15123, Maroussi, Athens, Greece

    Konstantinos P. Economopoulos & Theodoros N. Sergentanis

Authors
  1. Konstantinos P. Economopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodoros N. Sergentanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos P. Economopoulos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Economopoulos, K.P., Sergentanis, T.N. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 120, 211–216 (2010). https://doi.org/10.1007/s10549-009-0467-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0467-1

Keywords

Search

Navigation